In 2024, Venus Medtech (Hangzhou) completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Venus Medtech (Hangzhou) has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 31.32a | 88.82a | 70.21a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 3,183.96a | 4,020.62a | 4,357.5a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.4855a | 1.2847a | 1.2028a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Venus Medtech (Hangzhou) amounted to 3,215.28 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Venus Medtech (Hangzhou) decreased by 21.76%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Venus Medtech (Hangzhou) were 31.32 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Venus Medtech (Hangzhou)'s Scope 1 emissions have decreased by 56.72%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Venus Medtech (Hangzhou)'s Scope 1 emissions decreased by 64.74%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Venus Medtech (Hangzhou) reported Scope 2 greenhouse gas (GHG) emissions of 3,183.96 tCO₂e without specifying the calculation method.a
Since 2020, Venus Medtech (Hangzhou)'s Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 38.85%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), Venus Medtech (Hangzhou)'s Scope 2 emissions (Unspecified Calculation Method) fell by 20.81% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2024, Venus Medtech (Hangzhou) reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Venus Medtech (Hangzhou) reported Scope 1 greenhouse gas (GHG) emissions of 31.32 tCO₂e and total revenues of USD 65 millions. This translates into an emissions intensity of 0.49 tCO₂e per millions USD.a
In 2024, Venus Medtech (Hangzhou) reported a Scope 1 emissions intensity of 0.49 tCO₂e per millions USD. Compared to the peer group median of 2.78, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Venus Medtech (Hangzhou) ranked 4 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Venus Medtech (Hangzhou) among the top performers, with one of the lowest emissions intensities relative to peers.a